Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases.
作者信息
Macauley Shannon L, Sands Mark S
机构信息
Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
出版信息
Exp Neurol. 2009 Jul;218(1):5-8. doi: 10.1016/j.expneurol.2009.03.040. Epub 2009 Apr 8.
Abstract
摘要
相似文献
1
Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases.
Exp Neurol. 2009 Jul;218(1):5-8. doi: 10.1016/j.expneurol.2009.03.040. Epub 2009 Apr 8.
2
CNS-directed gene therapy for lysosomal storage diseases.
Acta Paediatr. 2008 Apr;97(457):22-7. doi: 10.1111/j.1651-2227.2008.00660.x.
3
Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.
Mol Ther. 2023 Mar 1;31(3):657-675. doi: 10.1016/j.ymthe.2022.11.015. Epub 2022 Nov 30.
4
Treating lysosomal storage disorders: current practice and future prospects.
Biochim Biophys Acta. 2009 Apr;1793(4):737-45. doi: 10.1016/j.bbamcr.2008.08.009. Epub 2008 Sep 5.
5
Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5760-2. doi: 10.1073/pnas.102175599.
6
Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.
Mol Ther. 2017 May 3;25(5):1155-1162. doi: 10.1016/j.ymthe.2017.03.025. Epub 2017 Apr 4.
7
Delivering Hematopoietic Stem Cell Gene Therapy Treatments for Neurological Lysosomal Diseases.
ACS Chem Neurosci. 2019 Jan 16;10(1):18-20. doi: 10.1021/acschemneuro.8b00408. Epub 2018 Aug 23.
8
Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective.
Int J Mol Sci. 2021 Nov 28;22(23):12870. doi: 10.3390/ijms222312870.
9
ERT Degrades Gene Therapy for Storage Disorder.
Mol Ther. 2019 Jul 3;27(7):1207-1208. doi: 10.1016/j.ymthe.2019.06.002. Epub 2019 Jun 13.
10
Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy.
Hum Mol Genet. 2019 Jun 1;28(11):1810-1821. doi: 10.1093/hmg/ddz020.
引用本文的文献
1
An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.
Ann Transl Med. 2019 Jul;7(13):289. doi: 10.21037/atm.2019.04.49.
2
Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease.
Mol Ther Methods Clin Dev. 2019 Jan 25;12:233-245. doi: 10.1016/j.omtm.2019.01.006. eCollection 2019 Mar 15.
3
Infantile Neuroaxonal Dystrophy: Diagnosis and Possible Treatments.
Front Genet. 2018 Dec 10;9:597. doi: 10.3389/fgene.2018.00597. eCollection 2018.
4
Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.
Pediatr Endocrinol Rev. 2016 Jun;13 Suppl 1(Suppl 1):639-48.
5
Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.
Orphanet J Rare Dis. 2016 Apr 16;11:40. doi: 10.1186/s13023-016-0414-2.
6
Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease).
J Child Neurol. 2013 Sep;28(9):1151-8. doi: 10.1177/0883073813495960.
7
Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).
Biochim Biophys Acta. 2013 Nov;1832(11):1906-9. doi: 10.1016/j.bbadis.2013.05.026. Epub 2013 Jun 6.
8
Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII.
Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17022-7. doi: 10.1073/pnas.1214779109. Epub 2012 Oct 1.
9
Bone marrow transplantation increases efficacy of central nervous system-directed enzyme replacement therapy in the murine model of globoid cell leukodystrophy.
Mol Genet Metab. 2012 Sep;107(1-2):186-96. doi: 10.1016/j.ymgme.2012.05.021. Epub 2012 Jun 1.
10
Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease.
Mol Ther. 2012 Jul;20(7):1393-9. doi: 10.1038/mt.2012.100. Epub 2012 May 15.
本文引用的文献
1
Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse.
Exp Neurol. 2009 May;217(1):124-35. doi: 10.1016/j.expneurol.2009.01.022. Epub 2009 Feb 10.
2
Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy.
Mol Ther. 2009 Apr;17(4):600-6. doi: 10.1038/mt.2008.305. Epub 2009 Jan 27.
3
Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease.
Exp Neurol. 2009 Feb;215(2):349-57. doi: 10.1016/j.expneurol.2008.10.021. Epub 2008 Nov 14.
4
Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration.
Exp Neurol. 2008 Dec;214(2):181-92. doi: 10.1016/j.expneurol.2008.07.026. Epub 2008 Aug 16.
5
Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice.
J Lipid Res. 2008 Aug;49(8):1646-57. doi: 10.1194/jlr.M700482-JLR200. Epub 2008 Apr 15.
6
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
Mol Ther. 2008 Apr;16(4):649-56. doi: 10.1038/mt.2008.9. Epub 2008 Feb 12.
7
Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse.
Exp Neurol. 2007 Oct;207(2):258-66. doi: 10.1016/j.expneurol.2007.06.017. Epub 2007 Jul 10.
8
Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.
Mol Ther. 2007 Oct;15(10):1782-8. doi: 10.1038/sj.mt.6300249. Epub 2007 Jul 17.
9
The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease.
J Inherit Metab Dis. 2007 Oct;30(5):654-63. doi: 10.1007/s10545-007-0632-9. Epub 2007 Jul 12.
10
Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse.
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9505-10. doi: 10.1073/pnas.0703509104. Epub 2007 May 21.
Zotero 插件